Genzyme

GenzymeGenzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

www.genzyme.com

Genzyme RSS Channel

Display # 
Title Published Date
Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards 06 January 2016
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care 05 October 2015
Genzyme recognizes World MS Day 30 May 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients 22 January 2012
Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration 16 November 2011
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis 12 July 2011
Genzyme Celebrates 20th Anniversary of Gaucher Disease Registry with Launch of New Web Platform 17 June 2011
Genzyme Revenues Grow in First-Quarter 2011 29 April 2011
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease 15 April 2011
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares 07 March 2011
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program 28 February 2011
Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year 16 February 2011
Genzyme Will Allow sanofi-aventis to Conduct Due Diligence 31 January 2011
Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme® 20 January 2011
Genzyme Financial Recovery Continues in Fourth Quarter 11 January 2011
Genzyme Statement on Discussions With Sanofi-Aventis 10 January 2011
Genzyme Details Market Potential of Alemtuzumab for MS 20 December 2010
Genzyme Reiterates Board's Position on sanofi-aventis Tender Offer 13 December 2010
Genzyme Completes Sale of Genetic Testing Business to LabCorp 01 December 2010
Genzyme Announces Agreement to Sell Diagnostics Business 18 November 2010

Most Popular Now

A new method cuts the cost of drug-…

EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical indu...

Read more

Six leading scientists to receive p…

Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbo...

Read more

Pfizer announces publication of new…

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid po...

Read more

Bayer and CRISPR Therapeutics joint…

Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therape...

Read more

AstraZeneca and Lilly receive FDA F…

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programm...

Read more

Natural compound from a deep-water …

Scientists at Florida Atlantic University's Harbor Branch Oceanographic Institute found that a deep-water marine sponge collected off of Fort Lauderdale's coast contains ...

Read more

Researchers develop safer opioid pa…

An international team of researchers - led by scientists at UC San Francisco, Stanford University, the University of North Carolina (UNC), and the Friedrich-Alexander Uni...

Read more

Amgen and Advaxis enter global canc…

Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical inve...

Read more

Legions of nanorobots target cancer…

Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research. They have develope...

Read more

Why is breast cancer common but hea…

Malignant cancers strike certain organs, such as the colon or breast, more often than others. In an Opinion publishing August 9 in Trends in Cancer, researchers propose t...

Read more

Pfizer to acquire small molecule an…

Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage sm...

Read more

Esketamine receives Breakthrough Th…

Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has gran...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

© World Pharma News 2006 - 2016